Company intelligence / Profile preview
AptaBio Therapeutics Inc.
Yongin-si, Gyeonggi-do, South Koreaaptabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's lead candidate isuzinaxib (APX-115) has shown positive topline data in European Phase 2 clinical trials for diabetic nephropathy and is also being evaluated for contrast-induced acute kidney injury. The company has multiple candidates in clinical and preclinical stages.
- Therapeutic areas
- GastroenterologyOncologyNephrologyOphthalmologyHematologyInfectious Diseases
- Modalities
- Small molecule drugsAptamer drug conjugatesChemical drugs
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Collaborations with universities, hospitals, contract research organizations and contract manufacturing organizations
Beyond the preview
Go deeper on AptaBio Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AptaBio Therapeutics Inc..